The Register · Issue One, October 2026
Washington Is Writing About the Channel, Not the Molecule
Six terms, one federal publication archive. The compound that defines the category returns 14 documents. The section of the law governing who may compound it returns 283. Regulatory exposure in this sector is channel exposure.
Read with Feature I, which shows how little registered development sits under most of these names, and with Feature III on what the paperwork will carry.
Six queries
On 2026-10-13 the Federal Register’s public interface was asked, for six terms, how many published documents mention the term and how those documents divide by type. The archive is the government’s own publication record: rules, proposed rules, notices and presidential documents, going back decades.
The compound that defines the commercial category returns 14 documents. The section of the Food, Drug, and Cosmetic Act that governs pharmacy compounding returns 283. The phrase outsourcing facility returns 136. Bulk drug substances returns 130. Compounded drug returns 124. Together those four channel terms account for 673 documents against 14 for the molecule.
The ratio is the story, and it is not subtle. Almost everything the federal government has published in this area concerns the machinery that gets a compounded substance to a person: which facility may make it, under which registration, from which starting material, under whose inspection. The molecule itself barely appears.
The compound’s route into the federal publication record runs through the compounding list, not through a file of its own.
There is a detail inside the 14 that makes the point better than the ratio does. Two of the five most recent documents mentioning semaglutide are editions of one recurring notice, the list of bulk drug substances for which there is a clinical need under section 503B. The compound’s route into the federal publication record runs through the compounding list, not through a file of its own.
Notice, not rule
Splitting each term by document type changes what the totals mean. Of the 124 documents mentioning compounded drug, 86 are notices and 17 are final rules. Of the 283 under section 503A, 191 are notices and 49 are final rules. For outsourcing facility the split is 123 notices to 6 final rules, which is 90.4% notice by volume.
A notice is an announcement: a guidance document has become available, a list has been revised, a meeting is scheduled, an information collection is proposed. A final rule is binding text. The published record in this area is, by a wide margin, the former.
That has a practical consequence for anyone holding a position in the channel. The binding instruments are few and slow. The thing that actually changes the operating environment is the notice stream, because that is where the lists move, and the lists are what determine which substances a facility may work from.
| Term as queried | Documents | Final rules | Proposed rules | Notices | Other types |
|---|---|---|---|---|---|
| Compounded drug | 124 | 17 | 21 | 86 | 0 |
| Section 503A | 283 | 49 | 37 | 191 | 6 |
| Outsourcing facility | 136 | 6 | 7 | 123 | 0 |
| Bulk drug substances | 130 | 10 | 20 | 98 | 2 |
| Peptide | 951 | 93 | 71 | 753 | 34 |
| Semaglutide | 14 | 0 | 1 | 13 | 0 |
What a mention is not
These counts are full-text mentions, and a mention is not a subject. On the retrieval date the most recent document returned for the term peptide was a proposed rule on clinical laboratory improvement amendments, and the one behind it a foreign-trade-zone production notice. Neither is about this sector. Both are listed, with their dates and links, in The Register. The 951 figure for peptide should be read as the ceiling of how often the word appears across every agency, not as a measure of regulatory attention.
The counts are cumulative across the whole archive, not annual. They say how much has been published, never how much is in force or how much was published lately. A term that was active twenty years ago and is quiet now looks identical here to one that is active today.
The type split does not always account for the whole total. For section 503A the three types sum to 277 against a term total of 283; for bulk drug substances, 128 against 130; for peptide, 917 against 951. The register classifies the remainder outside the three types counted here. Those remainders are shown in the table rather than quietly folded into one of the named categories.
Every count on this page was produced by a request that is printed in the sources block and stored, in full, in the published data file behind The Register.
The desk’s reading
This is the desk’s argument rather than a result, and the separation is deliberate.
None of those is a property of the molecule. All of them are properties of the channel.
An investor in this category is usually told they are taking molecule risk: will the compound clear its next stage, will the label hold, will the patent survive. The publication record says the live exposure for most operators is somewhere else entirely. It is whether a substance stays on a list, whether a facility keeps a registration, and whether a category of preparation stays permissible. None of those is a property of the molecule. All of them are properties of the channel.
That reframes what due diligence should look at. A position whose value depends on a compounding route is exposed to a notice, published on an ordinary morning, that revises a list. A position whose value depends on an approved application is exposed to a different and much slower process. Feature I showed that most names in this catalogue have no registered development behind them at all, which means most of them are in the first category whether or not anyone has said so out loud.
The most useful thing an operator can do with this page is boring and cheap: watch the notice stream for four terms rather than watching the compound.
Sources, and the queries that produced every figure above
- Federal Register API, version 1, documents endpoint. Office of the Federal Register, National Archives and Records Administration. Retrieved 2026-10-13. One full-text term query per tracked term, then one count query per document type for the same term. Counts cover the whole published archive, not a single year.https://www.federalregister.gov/api/v1/documents.json?conditions[term]=<term>&per_page=5&order=newest
- ClinicalTrials.gov Data API, version 2, studies endpoint. U.S. National Library of Medicine, National Institutes of Health. Retrieved 2026-10-13. One query per corpus compound name. totalCount is the number of study records the registry returns for the term on the retrieval date. The full result set, one row per compound with the URL that produced it, is published in data/quarterly/clinicaltrials.json.https://clinicaltrials.gov/api/v2/studies?query.intr=<compound name>&countTotal=true&pageSize=1